NBIX Assumed by Guggenheim -- Price Target Set at $207

gurufocus.com · 2026-10-06

Neurocrine Biosciences (NBIX) Analyst Rating Update On October 3, 2023, Neurocrine Biosciences (NBIX) received a "Buy" rating from Guggenheim analyst Delma C

TickrTrends take: Guggenheim's price target of 207 for NBIX aligns with TickrTrends' current undervalued assessment of the Healthcare sector company, suggesting analyst conviction that the stock has room to appreciate toward that level. Investors focused on valuation metrics should monitor whether NBIX moves toward the 207 target and track any changes to analyst coverage or price targets that might affect the undervalued designation. The coverage assumption by Guggenheim adds institutional research attention to a stock that valuation-focused analysts currently view as trading below intrinsic value.

Read the full story at gurufocus.com →